ID | 118560 |
著者 |
Yanamoto, Souichi
Nagasaki University
Michi, Yasuyuki
Tokyo Medical and Dental University
Otsuru, Mitsunobu
Nagasaki University
Inomata, Toru
The Nippon Dental University
Nakayama, Hideki
Kumamoto University
Nomura, Takeshi
Tokyo Dental College
Hasegawa, Takumi
Kobe University
Yamada, Shin-ichi
Shinshu University
Kusukawa, Jingo
Kurume University
Yamakawa, Nobuhiro
Nara Medical University
Hasegawa, On
Tokyo Medical University
Ueda, Michihiro
National Hospital Organisation Hokkaido Cancer Center
Kitagawa, Yoshimasa
Hokkaido University
Hiraki, Akimitsu
Fukuoka Dental College
Hasegawa, Toshihiro
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Ohiro, Yoichi
Hokkaido University
Kobayashi, Wataru
Hirosaki University
Asoda, Seiji
Keio University
Kobayashi, Takanori
Nagaoka Red Cross Hospital
Iino, Mitsuyoshi
Yamagata University
Fukuda, Masayuki
Akita University
Ishibashi-Kanno, Naomi
University of Tsukuba
Kawaguchi, Koji
Tsurumi University
Aijima, Reona
Saga University
Noguchi, Kazuma
Hyogo College of Medicine
Okura, Masaya
Saiseikai Matsusaka General Hospital
Tanaka, Akira
The Nippon Dental University
Sugiura, Tsuyoshi
Kagoshima University
Shintani, Yukari
Wakayama Medical University
Yagihara, Kazuhiro
Saitama Cancer Center
Yamashiro, Masashi
NTT Medical Center Tokyo
Ota, Yoshihide
Tokai University
Miyazaki, Akihiro
Sapporo Medical University
Takeshita, Akinori
Osaka University
Kawamata, Hitoshi
Dokkyo Medical University
Iwabuchi, Hiroshi
Kanagawa Dental University
Uchida, Kenichiro
Yamaguchi University
Umeda, Masahiro
Nagasaki University
Kurita, Hiroshi
Shinshu University
Kirita, Tadaaki
Nara Medical University
|
資料タイプ |
学術雑誌論文
|
抄録 | Introduction: In early-stage oral tongue squamous cell carcinoma (OTSCC), elective neck dissection (END) is recommended when occult lymph node metastasis is suspected; however, there is no unanimous consensus on the risks and benefits of END in such cases. The management of clinically node-negative (cN0) OTSCC remains controversial. This study, therefore, aimed to evaluate the efficacy of END and its impact on the quality of life (QoL) of patients with cN0 OTSCC.
Methods and analysis: This is a prospective, multicentre, nonrandomised observational study. The choice of whether to perform END at the same time as resection of the primary tumour is based on institutional policy and patient preference. The primary endpoint of this study is 3-year overall survival. The secondary endpoint are 3-year disease-specific survival, 3-year relapse-free survival and the impact on patient QoL. Propensity score-matching analysis will be performed to reduce selection bias. Ethics and dissemination: This study was approved by the Clinical Research Review Board of the Nagasaki University. The protocol of this study was registered at the University Hospital Medical Information Network Clinical Trials Registry. The datasets generated during the current study will be available from the corresponding author on reasonable request. The results will be disseminated internationally, through scientific and professional conferences and in peer-reviewed medical journals. |
掲載誌名 |
BMJ Open
|
ISSN | 20446055
|
出版者 | BMJ Publishing Group
|
巻 | 12
|
号 | 9
|
開始ページ | e059615
|
発行日 | 2022-09-13
|
備考 | 著者英表記誤記あり (誤)Iwabuchi Hiroshi→(正)Hiroshi Iwabuchi
|
権利情報 | This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
|
EDB ID | |
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
出版社版
|
部局 |
病院
|